Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

49.95 +0.25 (+0.50%)
Streaming Delayed Price Updated: 10:10 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
35 36 Next >
News headline image
1 Green Flag and 1 Red Flag for Bluebird Bio Stock ↗
The stock has been in the news lately. 
Via The Motley Fool
News headline image
Could CRISPR Therapeutics Stock Help You Become a Millionaire? ↗
There are plenty of reasons to be optimistic about CRISPR's future. 
Via The Motley Fool
News headline image
Cathie Wood Predicts Deflation In 2024, More AI And Tech Optimism — And Rate Cuts ↗
Cathie Wood believes deflation in 2024, aggressive rate cuts and technological progress will drive expansion. 
Via Benzinga
Topics Artificial Intelligence Economy
News headline image
3 Money-Saving Tricks for Investing in Biotech Stocks in 2024 ↗
Doing a little math and doing a little extra research can make a big difference. 
Via The Motley Fool
News headline image
I'm Begging You to Buy Stocks Before January -- Here's Why ↗
Some studies have shown a pattern of market gains in the month of January. 
Via The Motley Fool
News headline image
Where Will CRISPR Therapeutics Be in 5 Years? ↗
Does the recent approval make the stock a no-brainer buy? 
Via The Motley Fool
News headline image
After This Landmark Win, Is CRISPR Therapeutics a Buy? ↗
CRISPR Therapeutics stock already has advanced in the double digits this year. 
Via The Motley Fool
News headline image
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock? ↗
The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction. 
Via The Motley Fool
News headline image
6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy ↗
Should you buy CRISPR's stock on the dip? 
Via The Motley Fool
News headline image
Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock ↗
These stocks are currently going in different directions, but both could go up in a new bull market. 
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals Sitting on a Gold Mine? ↗
Vertex shares have climbed about 40% this year. 
Via The Motley Fool
News headline image
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief ↗
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy. 
Via InvestorPlace
News headline image
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow ↗
CRISPR Therapeutics stock has increased in the double digits this year. 
Via The Motley Fool
News headline image
3 Genomics Stocks to Unlock the Future of Medicine ↗
Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use. 
Via InvestorPlace
News headline image
Better Growth Stock: Archer Aviation or Prime Medicine? ↗
Which of these innovation-themed growth stocks is the better buy? 
Via The Motley Fool
News headline image
3 Healthcare Stocks That Could Help Make You a Millionaire ↗
These stocks each have reached an important turning point that could signal growth ahead. 
Via The Motley Fool
News headline image
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich ↗
It's important to choose companies involved in trends that have long-term potential. 
Via The Motley Fool
News headline image
2 Stocks That Could Turn $1,000 Into $3,500 in 10 Years ↗
These businesses are exciting and can also lead to outsized long-term returns. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall? ↗
The benefits from its first drug launch will trickle in slowly, at least at first. 
Via The Motley Fool
News headline image
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally ↗
These stocks could bring investors more than just a lump of coal for Christmas. 
Via The Motley Fool
News headline image
Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip ↗
This biotech could have more winners on the way. 
Via The Motley Fool
News headline image
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. 
Via InvestorPlace
News headline image
3 Small-Cap Stocks That Could Skyrocket 1000% by 2030 ↗
With the iShares Russell 2000 ETF (NYSE:IWM) on the move, investors should consider these small-cap stocks to buy. 
Via InvestorPlace
Topics ETFs
News headline image
Cathie Wood Just Dumped $40 Million of Coinbase Global (COIN) Stock ↗
Wood is moving away from fintech and Internet names like COIN stock. She's now favoring genomics and artificial intelligence companies. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
1 Biotech Stock That Could Be the Next Amgen ↗
The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen. 
Via The Motley Fool
News headline image
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences? ↗
Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now. 
Via The Motley Fool
News headline image
3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
News headline image
Cathie Wood's Ark Invest Sells Nearly $11.5M Worth Of Coinbase Shares As Bitcoin, Crypto Rally Loses Steam ↗
 
Via Benzinga
News headline image
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine ↗
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. 
Via Investor's Business Daily
News headline image
Could Intellia Therapeutics Become the Next CRISPR Therapeutics? ↗
Intellia is approaching the finish line. 
Via The Motley Fool
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.